SciBase

Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for early skin cancer detection

by

STOCKHOLM, Dec. 4, 2023 /PRNewswire/ —SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that it will continue its US coast-to-coast momentum with a collaboration agreement with the Skin and Cancer Reconstructive Surgery Center (“SCARS Center”) in California. This partnership will help further introduce Nevisense to a … Read more

Letter from the Chairman of the Board

by

Midsummer approaches and, as you know, Simon resigned a few weeks ago so we would like to give you a quick update on the recent progress at SciBase. STOCKHOLM, June 19, 2023 /PRNewswire/ — SciBase has, under Simons leadership, built a foundation for growth by developing two dermatology products with great potential. Many important advancements … Read more

Annual general meeting has been held in SciBase Holding AB (publ)

by

STOCKHOLM, May 17, 2023 /PRNewswire/ — Today, the annual general meeting of 2023 was held in SciBase Holding AB (publ) (the “Company” or “SciBase”). Below follows a summary of the resolutions passed at the annual general meeting. The annual general meeting resolved:            to adopt the profit and loss statement and the balance sheet and the group … Read more

Clarification regarding announcement of senior management changes in SciBase

by

STOCKHOLM, May 16, 2023 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders hereby clarifies the May 15th announcement that Simon Grant will leave his position as CEO for personal reasons. Simon will transition out of his role over the next six months but will remain formally … Read more

SciBase announces changes in senior management

by

STOCKHOLM, May 15, 2023 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that Simon Grant has resigned from his position as CEO for personal reasons and will be transitioning out of his role over the next six months. Simon Grant will remain available to … Read more